Overview
Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors. Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas. He serves on the scientific advisory board for a number of organizations including St. Baldricks and the Childhood Brain Tumor Foundation. He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries. The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines.
Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Glioma, Brain Stem Cancer, Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration.
His clinical research consists of co-authoring 62 peer reviewed articles and participating in 41 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 14 clinical trials in the study of Reticulohistiocytoma.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, Baltimore, MD 21287
Additional Areas of Focus
Dr. Cohen has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
40 Clinical Trials
Forbes Porter is a Medical Genetics specialist and a Pediatrics provider in Bethesda, Maryland. Dr. Porter is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Smith-Lemli-Opitz Syndrome, Niemann-Pick Disease, Reticulohistiocytoma, and X-Linked Creatine Deficiency.
William Gahl is a Medical Genetics specialist and a Pediatrics provider in Bethesda, Maryland. Dr. Gahl is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Oculocutaneous Albinism Type 2, Hermansky-Pudlak Syndrome, Oculocutaneous Albinism Type 1, Oculocutaneous Albinism, and Deep Brain Stimulation.
Johns Hopkins Children's Center
Dr. Zambidis is Associate Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Zambidis’ clinical expertise is in the treatment of disorders of the immune system, histiocytic disorders, hematologic malignancies, blood and bone marrow transplantation (BMT), and regenerative medicine. His research interest focuses on advancing our understanding of pluripotent stem cells– the ‘master’ stem cells that can generate any new cell or tissue that the body needs to repair itself. Dr. Zambidis earned his M.D./Ph.D. in the Medical Scientist Training Program at the University of Rochester, Rochester, N.Y. He completed his Pediatrics Residency in the Department of Pediatrics, Washington University, St. Louis, Missouri, and his clinical/research fellowships in Pediatric Hematology/Oncology at the Johns Hopkins Hospital and the National Cancer Institute at the NIH. Dr. Zambidis has been interested in the biology of stem cells since he came to Johns Hopkins, in 2001. As a Pediatric Hematology/Oncology fellow, he was one of the very first Hopkins investigators to work with human embryonic stem cells (hESCs), beginning shortly after they were made available to the biomedical research community, in 2002. Dr. Zambidis was awarded the first NIH K08 Clinician-Scientist Training Award specifically investigating the therapeutic potential of human pluripotent stem cells (2004). After joining the Hopkins faculty, in 2005, he developed an experimental model of the early formation process of human blood and blood vessels using human pluripotent stem cells. The Zambidis laboratory at the Johns Hopkins Institute for Cell Engineering focuses on understanding the developmental biology of human hemato-vascular and human pluripotent stem cells. More recently, his group completed studies on highly efficient methods for generating nonintegrated, human induced pluripotent stem cell (hiPSC) lines from myeloid progenitors. His group has developed novel hiPSC-based vascular therapies for retinopathies, and more recently derived a new class of human pluripotent stem cells in a naïve ground state with new functionalities with even greater potency and stronger regenerative capacities. As a BMT physician-scientist, his long-term goal is to use hESC, hiPSC, and related pluripotent stem cell technologies to not only treat severe degenerative diseases, but also to elucidate the biological nature of cancer and aging. Dr. Zambidis is rated as an Experienced provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Gaucher Disease, Reticulohistiocytoma, Rosai-Dorfman Disease, and Lymphofollicular Hyperplasia.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Brain Stem CancerDr. Cohen isDistinguished. Learn about Brain Stem Cancer.
- GliomaDr. Cohen isDistinguished. Learn about Glioma.
- MedulloblastomaDr. Cohen isDistinguished. Learn about Medulloblastoma.
- Advanced
- Denys-Drash Syndrome (DDS)Dr. Cohen isAdvanced. Learn about Denys-Drash Syndrome (DDS).
- Diffuse Midline Glioma H3 K27M-Mutant
- Embryonal Tumor with Multilayered Rosettes
- Ewing SarcomaDr. Cohen isAdvanced. Learn about Ewing Sarcoma.
- GangliogliomaDr. Cohen isAdvanced. Learn about Ganglioglioma.
- HepatoblastomaDr. Cohen isAdvanced. Learn about Hepatoblastoma.
- Experienced
- Adult Soft Tissue SarcomaDr. Cohen isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Bone Marrow AspirationDr. Cohen isExperienced. Learn about Bone Marrow Aspiration.
- Infantile NeutropeniaDr. Cohen isExperienced. Learn about Infantile Neutropenia.
- NeuroblastomaDr. Cohen isExperienced. Learn about Neuroblastoma.
- NeurofibromatosisDr. Cohen isExperienced. Learn about Neurofibromatosis.
- Neurofibromatosis Type 1 (NF1)Dr. Cohen isExperienced. Learn about Neurofibromatosis Type 1 (NF1).